That's usually how biotech company work, spend big up-front for R&D, get the product to commercialisation stage, staff cost usually decrease due to revenue coming in or they have to cut stuff or they sell their product if their revenue can't cover the cost, which AHZ is doing. This will allow them to spend on R&D on their other products.
Yes, AHZ.....they are starting to do it.
That's usually how biotech company work, spend big up-front for...
-
- There are more pages in this discussion • 95 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.49 |
Change
0.490(4.08%) |
Mkt cap ! $264.0M | |||
| Open | High | Low | Value | Volume |
| $12.11 | $12.49 | $11.50 | $155.8K | 13.16K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 175 | $11.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.49 | 77 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |